Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Phase I
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014 1:53:44 PM
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014 10:59:57 AM
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014 10:45:08 AM
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014 9:48:56 AM
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014 8:57:29 AM
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014 7:47:47 AM
Curis, Inc. (CRIS) Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors 12/18/2014 7:38:21 AM
Clementia Initiates First Prospective Natural History Study In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 12/17/2014 8:46:56 AM
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors 12/17/2014 8:17:31 AM
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data From Phase 1b Trial Of I.V. CR845 In Dialysis Patients 12/17/2014 7:26:13 AM
Alla Chem Completes Phase Ib/Iia Clinical Study With AV4025, An HCV NS5A Inhibitor 12/16/2014 3:56:36 PM
Prothena Receives FDA Fast Track Designation For NEOD001, A Monoclonal Antibody For The Treatment Of Patients With AL Amyloidosis 12/15/2014 10:53:45 AM
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014 8:08:48 AM
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014 8:07:45 AM
TetraLogic Pharmaceuticals (TLOG) Provides Update On Ovarian Cancer Study 12/16/2014 7:42:37 AM
1234567
//-->